Skip to content

Laser in treatment of resistant melasma, Intradermal tranexamic acid in treatment of resistant melasma

Comparison of the efficacy of Fractional Erbium: YAG laser and topical hyroquinone 4% versus intradermal tranexamic acid and topical hyroquinone 4% in treatment of resistant melasma

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20191011045057N1
Enrollment
27
Registered
2020-02-05
Start date
2019-09-22
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention 1: Intervention group: Laser therapy with topical treatment (4% hydroquinone cream) for the treatment of refractory melasma in one side of a person. Intervention 2: Intervention group: In

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Female patients with melasma with age ranging from 20 to 50 years Having informed consent to participate in the study No pregnancy or lactation No systemic diseases

Exclusion criteria

Exclusion criteria: Female patients with melasma younger than 20 years and over 50 years Lack of informed consent to participate in the study Pregnancy or lactation Systemic diseases

Design outcomes

Primary

MeasureTime frame
MASI score. Timepoint: Get started, one month later, two month later, three months later, three months after the end of treatment. Method of measurement: check list and examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahareh Bahrami

Esfahan University of Medical Sciences

bahar_bahrami45@yahoo.com+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 14, 2026